Press release: Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study See also: Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures Commentaries: What Moderna’s Covid-19 vaccine results mean for ending the pandemic – Vox AND Moderna follows Pfizer with […]

The post [Press release – not published yet] Moderna’s COVID-19 vaccine candidate shows 94.5% protection in an interim analysis of the phase 3 COVE study appeared first on Links Medicus.